These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 27372220

  • 1. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L.
    Drug Alcohol Depend; 2016 Aug 01; 165():221-8. PubMed ID: 27372220
    [Abstract] [Full Text] [Related]

  • 2. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.
    Drug Alcohol Depend; 2016 Nov 01; 168():219-229. PubMed ID: 27716575
    [Abstract] [Full Text] [Related]

  • 3. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M.
    Addiction; 2015 Feb 01; 110(2):226-37. PubMed ID: 25358480
    [Abstract] [Full Text] [Related]

  • 4. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.
    Clin Pharmacol Ther; 2016 Sep 01; 100(3):275-86. PubMed ID: 27170195
    [Abstract] [Full Text] [Related]

  • 5. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA, Thorley E, Black RA, DeVeaugh-Geiss A, Butler SF, Coplan P.
    J Opioid Manag; 2017 Sep 01; 13(6):425-440. PubMed ID: 29308589
    [Abstract] [Full Text] [Related]

  • 6. Pharmacy-related theft of controlled substances: RxPATROL® findings.
    Erensen JG, Haddox JD, Attre MS, Bauza LN.
    J Opioid Manag; 2018 Sep 01; 14(5):373-380. PubMed ID: 30387860
    [Abstract] [Full Text] [Related]

  • 7. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1589-98. PubMed ID: 24738694
    [Abstract] [Full Text] [Related]

  • 8. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.
    Cepeda MS, Fife D, Vo L, Mastrogiovanni G, Yuan Y.
    J Pain; 2013 Feb 01; 14(2):158-64. PubMed ID: 23253635
    [Abstract] [Full Text] [Related]

  • 9. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ, Ellis MS.
    JAMA Psychiatry; 2015 May 01; 72(5):424-30. PubMed ID: 25760692
    [Abstract] [Full Text] [Related]

  • 10. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
    Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD.
    Pharmacoepidemiol Drug Saf; 2013 Dec 01; 22(12):1274-82. PubMed ID: 24123484
    [Abstract] [Full Text] [Related]

  • 11. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG, Coplan PM.
    Postgrad Med; 2018 Aug 01; 130(6):568-574. PubMed ID: 29978755
    [Abstract] [Full Text] [Related]

  • 12. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS, Chang HY, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2015 Feb 01; 24(2):197-204. PubMed ID: 25393216
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.
    J Med Internet Res; 2014 May 02; 16(5):e119. PubMed ID: 24800858
    [Abstract] [Full Text] [Related]

  • 14. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US.
    Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC.
    Drug Saf; 2012 Apr 01; 35(4):325-34. PubMed ID: 22339505
    [Abstract] [Full Text] [Related]

  • 15. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM, Perrino PJ, Colucci SV, Harris SC.
    J Psychopharmacol; 2013 Sep 01; 27(9):808-16. PubMed ID: 23784739
    [Abstract] [Full Text] [Related]

  • 16. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD.
    Drug Alcohol Depend; 2014 Jun 01; 139():9-17. PubMed ID: 24721614
    [Abstract] [Full Text] [Related]

  • 17. Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries.
    Ponté C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, Micallef J.
    Drug Alcohol Depend; 2018 Jun 01; 187():88-94. PubMed ID: 29649695
    [Abstract] [Full Text] [Related]

  • 18. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
    Sankey C, Setnik B, Harsanyi Z, Michalko K, Yang Z, Geoffroy P.
    J Opioid Manag; 2016 Jun 01; 12(2):149-59. PubMed ID: 27194200
    [Abstract] [Full Text] [Related]

  • 19. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance B.
    Drug Alcohol Depend; 2015 Jun 01; 151():56-67. PubMed ID: 25910850
    [Abstract] [Full Text] [Related]

  • 20. Opioid shopping behavior: how often, how soon, which drugs, and what payment method.
    Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC.
    J Clin Pharmacol; 2013 Jan 01; 53(1):112-7. PubMed ID: 23400751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.